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Intestinal parasitic infections (IPIs) can be a severe threat to immunocompromised patients. This 
is particularly true for those undergoing chemotherapy and hemodialysis. The present research is 
aimed at identifying intestinal parasites that might be present in immunocompromised patients. In 
this cross-sectional study 1040 stool samples were collected (279 samples from hemodialysis 
patients, 362 samples from chemotherapy patients and 399 samples from the control group) from 
March to September 2017. The samples were tested by direct, formalin-ether methods for protozoa 
and ova of intestinal parasites and Ziehl-Neelsen staining methods for coccidian parasites such as 
Cryptosporidium species. The overall parasitic infection rate was higher (15%) in hemodialysis 
patients and 11.3% in chemotherapy patients whereas the lowest rate was observed (7.3%) in the 
control group. The infectivity rates were statistically significant (P = 0.008) when compared with 
the control group. The most prevalent parasites present were Blastocystis hominis (8.9% of the 
cases), Entamoeba coli (1.6%), Iodamoeba butschlii (0.8%), Endolimax nana (0.6%), Chilomastix 
mesnili (0.5%), Strongyloides stercoralis (0.5%) and Taenia species (0.15%), whereas Giardia 
lamblia was found present only in the control group. Statistical analyses revealed a significant 
correlation between gastrointestinal symptoms (such as some abdominal pain, diarrhea) and the 
ratio of chemotherapy frequency to scheduled frequency and parasitic infections (P = 0.001). There 
was not a correlation between prevalence of parasites with age or education levels of the infected 
individuals. Results of the present study suggest that a periodic stool examinations in special 
parasitological laboratories should be included as part of routine and general medical care.  
 





































































Intestinal parasitic infestations cause a variety of clinical conditions, the majority of which are 
related to the gastrointestinal (GI) tract. Intestinal parasites are among the most common human 
infections distributed worldwide (Bora 2016). One fourth of all known diseases are caused by 
parasites (Cleaveland Laurenson and Taylor 2001). 
There is evidence that some parasitic infections are associated with cancer development. The level 
of evidence of this association varies from high to low; in any case, a long time interval is 
mandatory for the development of cancer. Opisthorchis viverrini and Clonorchis sinensis are 
associated with cholangiocarcinoma, Schistosoma hematobium with bladder cancer (Samaras et 
al. 2010). According to the World Health Organisation (2019) certain viruses, bacteria, and 
parasites can act as biological carcinogens. It is suggested that in low- and middle-income 
countries as many as 15% of cancers diagnosed in 2012 could be attributed to carcinogenic 
infections; Martel et al. (2020) estimated for 2018, around 2.2 million infection-attributable 
cancers were diagnosed worldwide. According to Cancer Research UK (2020) bile duct cancer 
and bladder cancer can be directly attributed to parasites. 
Changes in social and cultural context have influenced the human-parasite relations during the past 
century. Currently, parasitic diseases are more prevalent in underdeveloped countries (Bloom and 
Murray 1992). Patients undergoing chemotherapy or hemodialysis are considered to be 
immunocompromised and specific steps in healthcare are followed to reduce the risk of infection 
(Ferreira and Borges 2002). It has been observed that healthy individuals could also be affected by 
intestinal parasites. They often express self-limiting symptoms, but they can increase the risk of 


































































Infections increase the mortality rates and it is considered as the second highest cause of mortality 
for hemodialysis patients (Tonelli et al. 2006). There is also evidence that there is a high rate of 
parasitic infections in cancer patients, especially those that undergo chemotherapy (Zabolinejad et 
al. 2013; Barazesh et al. 2015). Directing the awareness of physicians towards the early diagnosis, 
and rapid and proper treatment of such pathogens could reduce the morbidity and mortality rate as 
well as reducing the medical costs. 
The present study was conducted to investigate the prevalence of IPIs in two groups of patients 
(hemodialysis patients and chemotherapy patients), compared with the control (patients not 
diagnosed with those conditions) group.  
 
Material and Methods 
 
2.1. Ethics statement 
The cross-sectional study was approved by the Ethics Committee of Guilan University of Medical 
Sciences with ethics number of IR.GUMS.REC.1396.141.  
2.2. Study area and sample collection 
The patients who were eligible for the study, were informed about the research plan and their 
consent was taken before recruitment. Participants were refereed from Razi Hospital, Guilan 
Oncology Center, Kianmehr Hemodialysis Center, and Caspian Hemodialysis Center in Rasht, 
Guilan province. During this period, fresh stool samples were collected from 362 cancer patients, 
279 hemodialysis patients and 399 individuals (control group) who were without any signs and 
symptoms of malignancy. During the first stage, demographic data were collected (age, gender, 


































































the participants with cancer, the type of cancer, number of completed chemotherapy sessions 
undergone, the date of the first chemotherapy session was recorded. For the hemodialysis patients, 
the following parameters were self-reported: the number of sessions, the date of their first dialysis 
and the frequency of treatment was recorded. Participants that took anti-parasitic drugs, antibiotics, 
mineral oils, barium, bismuth and non-absorbable anti-diarrhea drugs two weeks prior were 
excluded from the study. The inclusion criteria for the control group were:  
1. Patients without chronic infections 
2. Cancer patients receiving at least one course of chemotherapy 
3. Hemodialysis patients at least three months post their first dialysis were included in the 
study.  
 
2.3. Stool sample examination 
 
Fecal samples were collected in specimen containers from each individual and were transferred to 
the Department of Parasitology, School of Medicine, Guilan University of Medical Sciences. 
Macroscopic investigation of stool samples was performed to detect mucus and blood. The 
microscopic screening included direct wet smear (saline preparation and iodine preparation) and 
formalin-ether concentration to detect intestinal amoeba and flagellate (Bora et al.2016; Garcia 
2007). The oocysts of coccidian parasites (Cryptosporidium spp., Isospora belli), were examined 
with a modified acid-fast technique using light microscopy with a magnification of 100× according 
to Garcia et al. (1983).  
 



































































The data were statistically analyzed using SPSS software (SPSS version 16). Differences between 




This study compares the prevalence of intestinal parasites between 641 immunocompromised 
patients (including 362 chemotherapy and 279 hemodialysis patients), and 399 ‘healthy’ subjects 
as defined above.  49.9% of the participants were female and 50.1% male and their age range was 
60-79 years old (Table 1).  For all groups the infection rates 13% (see Table 1). The IPI rates for 
the individual groups were 11.3%, 15% and 7.3% for chemotherapy patients, hemodialysis patients 
and the control group, respectively. The IPI rates were significantly different between the three 
groups (P = 0.008). Blastocystis hominis was the most prevalent (8.9%) parasite observed in 
patients followed by Entamoeba coli (1.6%), Iodamoeba butschlii (0.8%), Endolimax nana 
(0.6%), Chilomastix mesnili (0.5%), Strongyloides stercoralis (0.5%) and Taenia species (0.15%).  
In the present study, helminthes, namely S. stercoralis and Taenia species were the only 
pathogenic parasites detected in the patients. Similar to the patients, B. hominis was the most 
prevalent (8.9%) parasite observed in the control group, followed by G. lamblia (2%), I. butschlii 
(0.5%), E. coli (0.25%), E. nana (0.25%), and C. mesnili (0.25%).  The pathogenic protozoa, G. 
lamblia, was the only pathogenic parasite detected in the ‘control group (Table 2). Multiple 
infections were detected in five participants (four in the hemodialysis and one in the cancer group). 
In all multiple infection cases, B. hominis was a constant finding. The association among the 


































































presented in Table 3. The rate of IPI was significantly higher in rural, compared with urban 
residence (P = 0.001). However, demographic characteristics were not associated with the 
prevalence of IPIs (see Table 3).  For the hemodialysis group it appears that there is no significant 
correlation between the prevalence of IPIs and the length of time since diagnosis. The effect of the 
chemotherapy sessions on the IPI was also investigated. The cancer patients were grouped 
according to the planned chemotherapy sessions completed. Group one included participants that 
completed less than half of the planned session; the second group included participants that had 
completed half of the planted sessions and the third included participants that had completed more 
than half of the sessions. The rate of parasitic infection was 9.8%, 22.2% and 8.2% in the first, 
second and third group, respectively. The difference was statistically significant (p = 0.02).  
The rate of parasitic infection observed in patients with uterine and ovarian cancer (13.8%), 




The prevalence of intestinal parasites in chemotherapy patients, hemodialysis patients and the 
control group was 11.3%, 15%, and 7.3%, respectively. Rasti et al. (2017) reported IPI of 7.6% in 
cancer patients and 11.9% of IPIs in hemodialysis patients of Kashan, Iran. The main reason for 
the lower incidence in cancer patients compared with its prevalence in the hemodialysis patients 
may be because of the short-term effects of the drugs used in chemotherapy (Barazesh et al. 2015).  
Hemodialysis patients sometimes spend up to 20 years undergoing hemodialysis. Such long-term 
care increases the risk of contaminations, from parasitic infections including from the health care 


































































dialysis treatments have a high risk of acquiring infections through contact with nursing staff, 
equipment and materials, on surfaces or from hands (Kulik et al. 2008). The prevalence of 
intestinal parasites in the present study is lower than the prevalence that has been reported among 
immunocompromised and cancer patients in Turkey (43.7%), and Egypt (18%) (Baiomy et al. 
2010; Thom Kleinberg and Roghmann 2013), and hemodialysis patients in Brazil (45.1%) (Kulik 
et al. 2008).  The prevalence of parasitic infestation in patients with cancers in India was found to 
be 80%. However, there was not a control group in that study) (Bora et al. 2016).  The prevalence 
of IPIs was higher (10–63%) among the patients with different immunosuppressed status 
compared with the control group (Bora et al. 2016; Kulik et al. 2008; Al-Qobati Al-Maktari and 
Derhim 2012; Togeh et al. 2000; Al-Megrin 2010; Ashrafi Tahbaz and Rahmati 2010).  The wide 
variation of prevalence may be attributed to the differences in geographical distribution of 
parasites, sanitary practices, and different selection criteria of cases (Bora et al. 2016). In the 
present study, non-pathogenic intestinal protozoan, B. hominis was the most prevalent (8.9%) 
parasite observed in immunocompromised patients followed by E. coli (1.6%), I. butschlii (0.8%), 
E. nana (0.6%), C. mesnili (0.5%) (Table 2). B. hominis was found to be the most common 
intestinal parasite in all studied groups; G. lamblia was found once in the control group (Table 2). 
Similar findings have been reported in other studies (Bora et al. 2016; Kulik et al. 2008; Al-Qobati 
Al-Maktari and Derhim 2012; Togeh et al. 2000; Al-Megrin 2010; Ashrafi Tahbaz and Rahmati 
2010; Kazemi et al. 2013). B. hominis may act as a pathogen in immunocompromised subjects and 
lead to various types of infections (with or without symptoms). Water, pets, and vegetables are 
probably the main sources of infections. Research indicates that B. hominis may be the source of 
such infections (Rao et al.2003; Motta and Silva 2002; Stensvold et al.2007; Abdel-Hameed and 


































































coli, I. butschlii, E. nana, and C. mesnili, had the highest prevalence among the patients and control 
groups (Table 2). Giardia and Cryptosporidium are two important waterborne parasites 
(Mahmoudi et al. 2013; 2017). In previous studies, Cryptosporidium and Giardia (oo)cysts were 
detected in surface water samples in Guilan (Mahmoudi et al. 2013; 2015 2017).  But, examination 
of stool specimens with formalin ether and Ziehl – Neelsen staining revealed no positive 
Cryptosporidium oocyst in either of the three groups (Table 1). Infections by this protozoan have 
been related to poor-quality drinking water (Mahmoudi et al. 2017; Seyrafian et al. 2006; Botero 
et al. 2003; Chieffi et al. 1998), but it cannot be discounted that these patients acquired the parasites 
from contaminated water, despite the fact that in Guilan, water used by nearly 100% of the 
population is subject to quality control. The frequency of Cryptosporidium spp. in adult 
hemodialysis patients was reported 4.6% in Brazil (Kulik et al. 2008), 11.5% in Iran (Seyrafian et 
al. 2006), and 20.27% in Turkey (Turkcapar et al. 2002). In addition, in the present study, two 
pathogenic helminths, S. stercoralis (0.5%) and Taenia species (0.15%) were the only pathogenic 
parasitic helminthes detected in the examined patients. Strongyloidiasis is a soil transmitted 
endemic disease, and most immunocompromised patients are exposed to the infection and its side 
effects, such as diarrhea (Ashrafi Tahbaz and Rahmati 2010).   
We observed three cases (0.3%) of infection with this parasite in one hemodialysis and two cancer 
patients. The number of cases observed are lower than the number of cases reported in another 
study in Iran (9.7%) (Sharifdini et al. 2018). Undoubtedly, certain measures, such as not using 
human feces as fertilizer on farms, and health education for farmers could be recommendations 
for the reduction of worm infections and protection of public health. Most cases of infections were 
observed in males rather than females in all three groups, however, they were not statistically 


































































from females (Al-Qobati Al-Maktari and Derhim 2012; Kia et al. 2008; Sayyari et al. 2005). The 
IPIs were significantly different in relation to the age, where the prevalence rates of IPIs (12.5%) 
in the age group 60–79 years was higher than other age groups. In some similar studies, the highest 
prevalence was reported in the age group above 50 years (Barazesh et al.2015; Monsef et al. 2008). 
No significant relationship was observed between the prevalence of IPIs and gastrointestinal 
symptoms (such as some abdominal pain, diarrhea) (Table 1) and similar observations were 
reported by Naeini et al. (2012). The present research demonstrated no significant association 
between education level and IPIs prevalence (Table 3), which is in line with the finding of Brazesh 
et al. (2015). Nevertheless, several studies observed a significant relationship between education 
level and IPIs prevalence (Naeini et al. 2012; Choy et al. 2014; Daryani et al. 2012). The current 
study demonstrates a significant association between IPIs prevalence and residence (9.6% among 
438 patients living in cities and 18.7% among 203 patients living in rural areas). Omrai et al. (2015) 
found a recognizable relationship between IPIs prevalence and residence but Naeini et al. (2012) 
and Barazesh et al. (2015) found no significant difference between these two variables. The 
differences may be the result of agriculture activities and other effective factors on growth, 
reproduction and transmission of parasites in rural areas as compared with cities (Barazesh et al. 
2015; Naeini et al. 2012; Omrani et al. 2015). We separated hemodialysis participants according 
to length of time receiving the treatment into three categories: 1 – 12 months, 13 – 24 months and 
≥ 25 months. No significant correlation was observed between IPIs prevalence and hemodialysis 
duration. The association between PDSS (proportion of done sessions of chemotherapy to 
scheduled session) and IPIs prevalence was assessed by allocating the PDSS into three categories 
according to the chemotherapy cycles received: less, intermediate and more than half of 


































































more prevalent in members of the second category (more than two other categories) and the 
difference is statistically significant. Chandramathi et al. (2012) used the same categorization and 
demonstrated the higher prevalence of B. hominis and Microsporidium species in cancer patients 
during the intermediate chemotherapy cycles (Chandramathi et al. 2012). The poisonous effect of 
chemotherapy medicine on the immune system reduces the immune function (Koivusalo and 
Hietanen 2004; Solomayer et al. 2003), thus causing augmentation for the parasitic infection.  At 
the end of the therapy course, the anti-oxidant system of patients reacted to the poisonous effects 
of chemotherapy drugs, which may boost their immune system and eventually overcome the 
parasite (Chandramathi et al. 2012). We found 11.9% prevalence rate in cancer patients with 
different types of leukemia with the highest and the lowest rates of IPIs occurring in patients with 
uterine and ovarian cancer (13.8%) and lung cancer (4.8%), respectively (statistically insignificant 
difference). In India, Rudraparta et al. (1997) reported a 16.5% prevalence rate for IPIs in patients 
with gastrointestinal cancer. A prevalence rate of 35.9% in children with leukemia has been 
reported by Zaboli Nejad et al. (2013). The difference may be attributed to methods (direct and 
ELISA) used to diagnose parasitic infection, while we only used the direct method. This study 
revealed the prevalence of parasitic infections was higher in two immunocompromised groups 
(undergoing chemotherapy and hemodialysis) compared with the control group in the study area. 
Detection of intestinal protozoan could be used as indicators of poor hygiene practices (Chieffi et 
al. 1998).  
 
5. Conclusion 
Most of the observed protozoans in the present study were non-pathogenic. Intestinal pathogenic 


































































parasites is always possible in this study area. Given the fact that some endemic parasitic infections 
such as S. stercoralis may be lethal for immunocompromised patients, periodic parasitology 
examinations are highly recommended for hemodialysis and chemotherapy patients.  
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      Age group 
48 (4.6%) 19 (4.8%) 17 (4.7%) 12 (4.3%) 30≥ 
271 (26.05%) 110 (27.6%) 108 (29.8%) 53 (19%) 31-59 
554 (53.3%) 202 (50.6%) 188 (51.9%) 164 (58.8%) 60-79 
167 (16.05%) 68 (17%) 49 (13.5%) 50 (17.9%) 80≤ 
    Sex 
521 (50.1%) 190 (47.6%) 171 (47.2%) 160 (57.3%) male 
519 (49.9%) 209 (52.4%) 191 (52.8%) 119 (42.7%) female 
    Educational 
level 
726 (69.8%) 235 (58.9%)  277 (76.5%) 214 (76.7%) Primary 
school 
238 (22.9%) 129 (32.33%)  61 (16.9%) 48 (17.2%) High school 
76 (3.36%) 35 (8.77%) 24 (6.6%) 17 (6.1%) University 
    Location 
586 (56.3%) 248 (62.1%) 131 (36.2%) 207 (74.2%) city 











877 (84.3%) 358 (89.7%) 284 (78.5%) 235 (84.2%) No 
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Table 2: Prevalence of Intestinal parasitic infections and infection rate among 





















10 (1.6%) 3 (0.8%) 7 (2.5%) Entamoeba coli  
 1 
(0.25%) 
4 (0.6%) 2 (0.6%) 2 (0.7%) Endolimax nana  
 2 
(0.5%) 





3 (0.5%) 1 (0.3%) 2 (0.7%) Chilomastix 
mesnili 
 
 8 (2%) 0 (0%) 0 (0%) 0 (0%) Giardia lamblia  
 0 (0%) 0 (0%) 0 (0%) 0 (0%) Cryptosporidium 
spp.  
 
 0 (0%) 3 (0.5%) 2 (0.55%) 1 (0.36%) Strongyloides 
stercoralis 
 





83 (13%) 41 (11.3%) 42 (15%) Infected   
 370 
(92.7%) 
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(932) N (%)  
 







Variable                         
       Age group 
 48 (100%) 42 (87.5%) 6 (12.5%) 30≥ 
0.43 271 (100%) 245 (90.4%) 26 (9.6%) 31-59 
 554 (100%) 490 (88.4) 64 (11.6%) 60-79 
 167 (100%) 155 (92.8%) 12 (7.2%) 80≤ 
      Sex 
0.78 521 (100%) 465 (89.3%) 56 (10.7%) male 
 519 (100%) 467 (89.8%) 52 (10.2%) female 
       Educational level 
 726 (100%) 645 (88.9%) 81 (11.1%) Primary school 
0.87 238 (100%) 220 (92.4%) 18 (7.6%) High school 
 76 (100%) 67 (88.2%) 9 (11.8%) University 
       Location 
0.001 586 (100%) 541 (92.3%) 45 (7.7%) urban 
 454 (100%) 391 (86.1%) 63 (13.9%) rural 
       Symptoms  
0.001 877 (100%) 801 (91.3%) 76 (8.7%) No 
 163 (100%) 131 (80.4%) 32 (19.6%) Yes 
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